Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $71.78 Analyst target: $266.67 Upside: 271.51%
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla, California.
See the full interactive analysis & chart →Informational only — not investment advice.